Bibliographic citations
Motta, A., Horna, J. (2022). Asociación entre los Índices Linfocitarios y Cardiotoxicidad en pacientes con cáncer de mama que recibieron quimioterapia en una clínica peruana 2016-2019 [Tesis, Universidad Peruana de Ciencias Aplicadas (UPC)]. http://hdl.handle.net/10757/659530
Motta, A., Horna, J. Asociación entre los Índices Linfocitarios y Cardiotoxicidad en pacientes con cáncer de mama que recibieron quimioterapia en una clínica peruana 2016-2019 [Tesis]. PE: Universidad Peruana de Ciencias Aplicadas (UPC); 2022. http://hdl.handle.net/10757/659530
@misc{renati/1291996,
title = "Asociación entre los Índices Linfocitarios y Cardiotoxicidad en pacientes con cáncer de mama que recibieron quimioterapia en una clínica peruana 2016-2019",
author = "Horna Illatopa, José Victor",
publisher = "Universidad Peruana de Ciencias Aplicadas (UPC)",
year = "2022"
}
Background: Lymphocyte indices, neutrophil-lymphocyte (NLI), monocyte- lymphocyte (MLI) and platelet-lymphocyte (PLI) are inflammatory markers of prognostic value on cardiovascular diseases. Our goal is to evaluate the relation between the lymphocyte indices and the development of cardiotoxicity on patients with breast cancer who received chemotherapy between 2016-2019. Methods: Retrospective cohort study based on the revision of echocardiogram and labs results among women ≥18 years old with confirmed breast cancer diagnosis who received chemotherapy in a Peruvian clinic between 2016-2019. Cardiotoxicity during chemotherapy was defined as ≥10% reduction in the left ventricle ejection fraction, ≥20% reduction of myocardial strain, or new left ventricle dysfunction. NLI was calculated as the quotient between the absolute neutrophil and lymphocyte counts in the most recent complete blood count before chemotherapy. MLI and PLI were calculated similarly. Association was evaluated by means of crude and adjusted Relative Risks (RR) with their 95% confidence intervals (95%CI), using Poisson regression with robust variance. Results: 418 women with breast cancer received chemotherapy and had echocardiographic evaluations. 176 were excluded because they lacked follow- up echocardiograms. From the 242 participants, the mean age was 56.5 (SD 12.3). Cumulative cardiotoxicity incidence was 12.4% during chemotherapy. There was association with hypertension and diabetes in the bivariate analysis. No association with any of the Lymphocyte indices was found in the adjusted models. The RR for each additional NLI point was 1.06 (95%CI 0.95-1.19). Conclusions: There was no association between cardiotoxicity during the chemotherapy with the Lymphocyte indices. More studies with more participants are needed in order to really determine if there is no association with the studied indices.
This item is licensed under a Creative Commons License